MA66471B1 - Formes cristallines de dérivés de quinazoline, leur préparation, leur composition et leur utilisation - Google Patents

Formes cristallines de dérivés de quinazoline, leur préparation, leur composition et leur utilisation

Info

Publication number
MA66471B1
MA66471B1 MA66471A MA66471A MA66471B1 MA 66471 B1 MA66471 B1 MA 66471B1 MA 66471 A MA66471 A MA 66471A MA 66471 A MA66471 A MA 66471A MA 66471 B1 MA66471 B1 MA 66471B1
Authority
MA
Morocco
Prior art keywords
crystalline forms
preparation
composition
quinazoline derivatives
methoxyquinazolin
Prior art date
Application number
MA66471A
Other languages
English (en)
Inventor
Zheng Wang
Ding Zhou
Ziqiang CHENG
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of MA66471B1 publication Critical patent/MA66471B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/14—Adipic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/185—Saturated compounds having only one carboxyl group and containing keto groups
    • C07C59/225—Saturated compounds having only one carboxyl group and containing keto groups containing —CHO groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des formes cristallines de (R)-N- (4- ([1, 2, 4] triazolo [1, 5-c] pyrimidin-7-yloxy)-3-méthylphényle)-5-((3, 3-difluoro-1-méthylpipéridin-4-yl)) oxy)-6-méthoxyquinazolin-4-amine, des procédés pour leur préparation, des compositions pharmaceutiques comprenant une ou plusieurs des formes cristallines en tant que principe actif, et l'utilisation des formes cristallines dans le traitement de maladies hyperprolifératives.
MA66471A 2021-10-20 2022-10-19 Formes cristallines de dérivés de quinazoline, leur préparation, leur composition et leur utilisation MA66471B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2021125016 2021-10-20
PCT/CN2022/126169 WO2023066296A1 (fr) 2021-10-20 2022-10-19 Formes cristallines de dérivés de quinazoline, leur préparation, leur composition et leur utilisation
EP22882901.6A EP4399207B1 (fr) 2021-10-20 2022-10-19 Formes cristallines de dérivés de quinazoline, leur préparation, leur composition et leur utilisation

Publications (1)

Publication Number Publication Date
MA66471B1 true MA66471B1 (fr) 2026-02-27

Family

ID=86057927

Family Applications (1)

Application Number Title Priority Date Filing Date
MA66471A MA66471B1 (fr) 2021-10-20 2022-10-19 Formes cristallines de dérivés de quinazoline, leur préparation, leur composition et leur utilisation

Country Status (25)

Country Link
US (1) US20240417403A1 (fr)
EP (2) EP4399207B1 (fr)
JP (2) JP2024539212A (fr)
KR (1) KR20240090181A (fr)
CN (4) CN120309621A (fr)
AU (1) AU2022371540A1 (fr)
CA (1) CA3232101A1 (fr)
CL (1) CL2024001231A1 (fr)
CO (1) CO2024004745A2 (fr)
CR (1) CR20240163A (fr)
DK (1) DK4399207T3 (fr)
ES (1) ES3059167T3 (fr)
FI (1) FI4399207T3 (fr)
HR (1) HRP20260049T1 (fr)
IL (1) IL312004A (fr)
LT (1) LT4399207T (fr)
MA (1) MA66471B1 (fr)
MX (1) MX2024004738A (fr)
PE (1) PE20242106A1 (fr)
PL (1) PL4399207T3 (fr)
PT (1) PT4399207T (fr)
RS (1) RS67641B1 (fr)
SI (1) SI4399207T1 (fr)
SM (1) SMT202600023T1 (fr)
WO (1) WO2023066296A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3213079A1 (fr) 2021-04-13 2022-10-20 Kristin Lynne ANDREWS Heterocycles amino-substitues pour le traitement de cancers avec des mutations egfr
WO2025195333A1 (fr) 2024-03-19 2025-09-25 F. Hoffmann-La Roche Ag Formulation pharmaceutique d'inhibiteurs d'erbb2

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
WO1997030035A1 (fr) 1996-02-13 1997-08-21 Zeneca Limited Derives de la quinazoline utilises comme inhibiteurs du vegf
ES2169355T3 (es) 1996-03-05 2002-07-01 Astrazeneca Ab Derivados de 4-anilinoquinazolina.
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
CA2755268C (fr) * 2005-11-15 2013-12-31 Array Biopharma, Inc. Inhibiteurs erbb
WO2017148391A1 (fr) * 2016-03-01 2017-09-08 上海医药集团股份有限公司 Composé hétérocyclique azoté, procédé de préparation, intermédiaire, composition et utilisation
EP3516071B1 (fr) * 2016-09-22 2021-02-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédé et compositions pharmaceutiques de traitement du cancer du poumon
AR117424A1 (es) * 2018-05-08 2021-08-04 Dizal Jiangsu Pharmaceutical Co Ltd Inhibidores de los receptores erbb
HUE065578T2 (hu) * 2018-09-18 2024-06-28 Hoffmann La Roche Kinazolin-származékok, mint daganatellenes szerek

Also Published As

Publication number Publication date
EP4399207B1 (fr) 2025-11-26
RS67641B1 (sr) 2026-02-27
CR20240163A (es) 2024-06-12
PT4399207T (pt) 2026-01-16
IL312004A (en) 2024-06-01
HRP20260049T1 (hr) 2026-02-27
PE20242106A1 (es) 2024-10-28
CO2024004745A2 (es) 2024-04-29
EP4717689A2 (fr) 2026-04-01
FI4399207T3 (fi) 2026-01-28
ES3059167T3 (en) 2026-03-19
US20240417403A1 (en) 2024-12-19
PL4399207T3 (pl) 2026-03-23
MX2024004738A (es) 2024-05-14
EP4399207A1 (fr) 2024-07-17
SI4399207T1 (sl) 2026-04-30
CN120309620A (zh) 2025-07-15
CL2024001231A1 (es) 2024-08-09
SMT202600023T1 (it) 2026-03-09
DK4399207T3 (da) 2026-02-02
JP2024539212A (ja) 2024-10-28
CN120623183A (zh) 2025-09-12
JP2026027273A (ja) 2026-02-18
CN119317625A (zh) 2025-01-14
LT4399207T (lt) 2026-02-10
CN120309621A (zh) 2025-07-15
WO2023066296A1 (fr) 2023-04-27
CA3232101A1 (fr) 2023-04-27
KR20240090181A (ko) 2024-06-21
AU2022371540A1 (en) 2024-03-21
EP4399207A4 (fr) 2025-03-19

Similar Documents

Publication Publication Date Title
MA59379B1 (fr) Aminothiazoles substitués en tant qu'inhibiteurs de dgkzeta pour l'activation immunitaire
US10398725B2 (en) Ophthalmic compositions and methods of use
CA2330500A1 (fr) Compositions pharmaceutiques gelifiables
TNSN05298A1 (fr) Derives de pyrazolo-quinazoline, procede pour leur preparation et leur utilisation comme inhibiteurs de kinases
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
MA47079A (fr) Composés amino-triazolopyidines et leur utilisation pour traiter le cancer
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
MA31283B1 (fr) Produits dérivés de 2,3-dihydroimidazo[1,2-c]quinazoline substitués, utiles pour le traitement de troubles hyperlifératifs et de maladies associées à une angiogénèse
MA27385A1 (fr) Therapie combinee de maladies hyperproliferatives.
MA28064A1 (fr) Dérivés de pyrrolo [3,4-c] pyrazole actifs comme inhibiteurs de kinases
MA33365B1 (fr) Dérivés de spiro[2.4]heptane pontés utiles en tant qu'agonistes du récepteur de alx et/ou du récepteur fprl2
MA30084B1 (fr) Triazolopyridazines en tant que modulateurs de la tyrosine kinase
CZ359498A3 (cs) Kompozice a její použití k přípravě farmaceutického prostředku pro léčení infekčních onemocnění a farmaceutický přípravek tuto kompozici obsahující
MA31949B1 (fr) Dérivés d'aminotriazole comme agonistes d'alx
US10314914B2 (en) Iodophor composition and methods of use
MA26960A1 (fr) Sels d'un isothiazole-4-carboxamide et leur utilisation comme agent anti-hyperproliferation
BR0312000A (pt) Compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, uso dos compostos
KR20040078663A (ko) 난청의 치료 방법
MA27093A1 (fr) Derives de sulfonamides, leur preparation et leur application comme medicaments.
MA34158B1 (fr) Combinaisons contenant une 2,3-dihydroimidazo{1,2-c]quinazoline substituée
MA52154B1 (fr) Composition pharmaceutique pour l'anémie
MA46268B1 (fr) Dérivés de 5-[2-(pyridin-2-ylamino)-1 ,3-thiazol-5-yl]-2,3-dihydro-1h-isoindol-1-one et leur utilisation en tant qu'inhibiteurs doubles de phosphatidylinositol 3-kinase delta & gamma
MA70477B1 (fr) Composés amido hétéroaromatiques utiles dans le traitement de maladies hépatiques
MA39186A1 (fr) Dérivés de [1,2,4]triazolo[1,5-a]pyrimidine utilisés comme inhibiteurs du protéasome des protozoaires pour le traitement de maladies parasitaires comme la leishmaniose
EP3067052A3 (fr) Nouveaux schémas d'administration de multithérapies utiles pour le traitement des personnes atteintes du virus de l'immunodéficience humaine (vih)